Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Molecular tumour board: Where do we stand? What’s next?

Building of a comprehensive clinical and molecular genomics database for patients with treatment-refractory cancers enrolled in clinical trials


29 Sep 2019


Molecular tumour board: Where do we stand? What’s next?


Targeted Therapy

Tumour Site


Philippe Bedard


P. Bedard

Author affiliations

  • Medical Oncology & Haematology, Princess Margaret Cancer Center, M5G 2M9 - Toronto/CA


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.